Acadia Pharmaceuticals, based in San Diego, was the subject of a Zacks analyst survey regarding earnings on August 7, 2025.
4 reports, 2 independent
Updated Jun 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Acadia Pharmaceuticals, based in San Diego, was the subject of a Zacks analyst survey regarding earnings on August 7, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Acadia Pharmaceuticals and Genmab A/S Sponsored ADR were analyzed for value investment potential on August 1, 2025.Sub-event
Zacks surveyed analysts regarding earnings for Acadia Pharmaceuticals, a San Diego-based company.1 source
Keep exploring
The entities involved
-
Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.
Nothing else this week.
-
San Diego
seat of San Diego County, California, United States; second-largest city in California
Related events
- BlossomHill Therapeutics, Inc. has established its operational base in San Diego.
- RF Industries, Ltd is headquartered in San Diego and has additional operations in Rhode Island.
- A company is establishing a presence through community development in Baja California, informational dinners in San Diego, and operations in Southern California.
- A news release was issued in San Diego involving Nasdaq on September 15, 2026.
- A consultant residing in San Diego works professionally in Los Angeles.
Coverage
Newest first; wire copies grouped- Associated Press FinanceAcadia: Q2 Earnings Snapshot SAN DIEGO (AP) — SAN DIEGO (AP) — Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported second-quarter net income of $26.7 million. The San Diego-based company said it
- ZacksAcadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus Estimate
- Unknown outlet